menu
    • menu

    Company profile for Elutia

    NEW Drugs in Dev: 2
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. Elutia offers a proprietary drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, perfected for device implantation and soft tissue reconstruction. Our offerings, CanGaroo for implantable electronic devices and SimpliDerm for soft-tissue reconst...
    Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. Elutia offers a proprietary drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, perfected for device implantation and soft tissue reconstruction. Our offerings, CanGaroo for implantable electronic devices and SimpliDerm for soft-tissue reconstruction, provide robust, but easy-to-use constructs that ensure implant stability and promote wound healing.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ElutiaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904
    Telephone
    Telephone
    +1 2402471170
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://elutia.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PCHi

    PCHi

    Not Confirmed

    envelop Contact Supplier

    PCHi

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Elutia To Present At Sidoti Small-Cap Investor Conference
    Elutia To Present At Sidoti Small-Cap Investor Conference

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257107/0/en/Elutia-to-Present-at-Sidoti-s-Small-Cap-Virtual-Investor-Conference-March-18-19.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Elutia Grants Inducement Awards Under Nasdaq LR 5635(C)(4)
    Elutia Grants Inducement Awards Under Nasdaq LR 5635(C)(4)

    13 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/13/3255424/0/en/Elutia-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    13 Mar 2026
    Share Share
    Elutia Reports Q4/FY Results, Launches NXT-41 Regulatory Process
    Elutia Reports Q4/FY Results, Launches NXT-41 Regulatory Process

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3254134/0/en/Elutia-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-Initiates-NXT-41-Regulatory-Process.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Elutia Regains Compliance With Nasdaq Listing Requirements
    Elutia Regains Compliance With Nasdaq Listing Requirements

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249320/0/en/Elutia-Regains-Compliance-with-Nasdaq-Listing-Requirements.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share
    Elutia To Release Q4 2025 Financial Results On March 11, 2026
    Elutia To Release Q4 2025 Financial Results On March 11, 2026

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3245015/0/en/Elutia-to-Report-Fourth-Quarter-2025-Financial-Results-on-Wednesday-March-11-2026.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Elutia Achieves 2026 Great Place To Work Certification
    Elutia Achieves 2026 Great Place To Work Certification

    18 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/18/3240174/0/en/Where-Purpose-Meets-Performance-Elutia-Earns-2026-Great-Place-to-Work-Certification.html

    GLOBENEWSWIRE
    18 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search